Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug...

Area of Science:

• Pharmaceutical marketing and physician prescribing behavior.
• Regulatory affairs and drug promotion.
• Evidence-based medicine and clinical decision-making.

Background:

• Recent legal decisions challenge the Food and Drug Administration's (FDA) regulations on manufacturer promotion of prescription drugs for unapproved uses.
• This study investigates the influence of promotional information on physicians' perceptions of drug efficacy for off-label indications.

Purpose of the Study:

• To assess how pro forma disclosures or descriptive evidence context about off-label claims affect physicians' beliefs regarding drug efficacy.
• To evaluate the impact of manufacturer-provided information on off-label prescribing patterns.

Main Methods:

• National samples of cardiologists, internists, and endocrinologists were randomized to receive information scenarios about a hypothetical drug (Vascepa).
• Scenarios included approved indication, off-label claim with pro forma disclaimers, or off-label claim with evidence context.
• Physicians' reported receipt of off-label information and off-label prescribing were recorded.

Main Results:

• 29% of physicians reported receiving off-label information about Vascepa, and 16% had prescribed it off-label.
• Off-label prescribing was significantly higher among physicians who received off-label information (38% vs. 7%).
• Physicians endorsing the unproven claim of cardiovascular risk reduction was similar with pro forma disclaimers (35-37%) but lower with evidence context (21%).

Conclusions:

• Physicians receiving manufacturer information on unapproved uses were more likely to prescribe off-label.
• Supplementing off-label claims with evidence context improved prescribers' understanding and reduced enthusiasm for unproven indications.